This page lists the cardiothoracic & vascular surgery hospitals in our directory offering Angioplasty & Stenting in Dubai, UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about angioplasty & stenting in Dubai, UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Cardiothoracic & Vascular Surgery in Dubai, UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Cardiothoracic & Vascular Surgery is among its listed specialties and it is located in Dubai, UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Angioplasty & Stenting in Dubai, UAE?
Choosing the right hospital for angioplasty & stenting is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cardiothoracic & vascular surgery rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Angioplasty & Stenting
Angioplasty and coronary stenting is a minimally invasive, catheter-based procedure used to restore blood flow through narrowed or blocked coronary arteries, achieving procedural success rates exceeding 95% in high-volume cardiac centres. International patients choose India and the UAE for this intervention because both destinations combine internationally accredited hospitals, experienced interventional cardiologists, and significantly lower out-of-pocket costs compared to the United States, United Kingdom, or Western Europe. GAF Healthcare coordinates end-to-end care across leading cardiac institutions in both countries, giving patients access to drug-eluting stent technology, intravascular imaging guidance, and seamless logistical support from first inquiry through post-discharge follow-up. Hospital Stay: 2–4 days (1 day in ICU/CCU observation post-procedure, followed by 1–3 days on a monitored cardiac ward) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (short-haul flights generally permitted after 5–7 days if the patient is haemodynamically stable and on optimised dual antiplatelet therapy; long-haul intercontinental flights advised after 10–14 days with cardiologist clearance and compression stocking use) • Success Rate: 95–98% procedural success rate for elective percutaneous coronary intervention (PCI); major adverse cardiovascular event (MACE) rates at 1 year below 5% with modern drug-eluting stents
Clinical Overview
Coronary artery disease (CAD) develops when atherosclerotic plaques — composed of lipid cores, inflammatory cells, fibrous caps, and calcium deposits — accumulate within the intimal layer of the epicardial coronary arteries. Progressive luminal narrowing (stenosis) restricts myocardial perfusion, producing stable angina pectoris at exertion thresholds proportional to the degree of ischaemia. When a vulnerable plaque ruptures or erodes, acute platelet aggregation and thrombus formation can precipitate an acute coronary syndrome (ACS), encompassing unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or the most time-critical emergency, ST-elevation myocardial infarction (STEMI). Left untreated, sustained ischaemia leads to irreversible myocardial necrosis, ventricular remodelling, heart failure, and potentially fatal arrhythmias. Percutaneous coronary intervention (PCI) — the umbrella term for balloon angioplasty and coronary stenting — is the globally accepted revascularisation standard for most presentations of obstructive CAD. Under fluoroscopic guidance, an interventional cardiologist advances a guide catheter through the radial or femoral artery to the coronary ostium, crosses the culprit lesion with a 0.014-inch guidewire, inflates a semi-compliant balloon (plain old balloon angioplasty, POBA) to compress the plaque, and then deploys a metallic stent to scaffold the vessel and prevent elastic recoil. Contemporary drug-eluting stents (DES) — third-generation devices coated with antiproliferative agents such as everolimus, zotarolimus, or sirolimus on biodegradable polymer platforms — release drug locally to inhibit neointimal hyperplasia, reducing in-stent restenosis rates to below 5% at one year. The standard of care for patient selection is evidence-based risk stratification using validated tools: the SYNTAX Score II for multivessel disease (guiding the PCI-versus-CABG decision), the GRACE score for ACS mortality risk, the TIMI risk score, and the EuroSCORE II for surgical risk. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) measurements are used to confirm the haemodynamic significance of intermediate stenoses (40–70%) before committing to stent implantation. Intravascular imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) is increasingly standard to optimise stent sizing, confirm full apposition, and rule out edge dissection — directly reducing the risk of stent thrombosis and target lesion failure.
Who is a Candidate?
• ELIGIBLE PATIENTS — STABLE CAD: - Symptomatic stable angina refractory to optimal medical therapy (beta-blockers, calcium channel blockers, long-acting nitrates) with objective evidence of myocardial ischaemia on non-invasive stress testing (exercise ECG, stress echocardiography, nuclear myocardial perfusion imaging [MPI/SPECT], or cardiac MRI perfusion) - Single-vessel or two-vessel CAD with a SYNTAX Score ≤22 where anatomy is suitable for PCI (Class I, ESC/ACC/AHA guidelines) - Significant left main coronary artery (LMCA) disease with a SYNTAX Score ≤22 and a Heart Team consensus favouring PCI over CABG • ELIGIBLE PATIENTS — ACUTE CORONARY SYNDROME: - STEMI within 12 hours of symptom onset: primary PCI (pPCI) is the preferred reperfusion strategy (door-to-balloon time target <90 minutes) - High-risk NSTEMI/unstable angina: early invasive strategy (coronary angiography within 24 hours) per GRACE score >140 or positive troponin - Cardiogenic shock complicating MI: emergent PCI of the culprit vessel • REQUIRED PRE-PROCEDURAL DIAGNOSTICS: - 12-lead ECG and continuous cardiac monitoring - High-sensitivity troponin I or T (serial measurements at 0, 1, and 3 hours for ACS rule-in/rule-out) - Transthoracic echocardiogram (2D/3D Echo with Doppler): to assess left ventricular ejection fraction (LVEF), regional wall motion abnormalities, valvular function, and pericardial effusion - Coronary CT angiography (CCTA) with CT-FFR (HeartFlow analysis): increasingly used for non-invasive anatomical and functional assessment of stable CAD before deciding on invasive catheterisation - Renal function panel (eGFR, serum creatinine): mandatory before contrast administration; patients with eGFR <30 mL/min require pre-hydration and minimised contrast volume - Full blood count, coagulation profile (INR, aPTT), liver function tests, and HbA1c - Chest X-ray (PA view) - Carotid Doppler ultrasound if peripheral vascular disease is suspected • CONTRAINDICATIONS: - Absolute: patient refusal or inability to comply with dual antiplatelet therapy (DAPT) for 6–12 months; active life-threatening bleeding; no arterial access route available - Relative: diffuse multivessel CAD with high SYNTAX Score (>33) where CABG provides superior long-term survival benefit (Heart Team decision required); severe uncorrected contrast allergy not manageable with premedication; severely impaired renal function without dialysis backup; severe uncorrected coagulopathy - Anatomical: chronic total occlusion (CTO) with unfavourable anatomy, extremely tortuous or heavily calcified vessels (though rotational atherectomy or laser atherectomy can address calcification in experienced centres)
Treatment Options & Approaches
STANDARD PCI — BALLOON ANGIOPLASTY AND DRUG-ELUTING STENTING: The foundational approach involves radial artery access (preferred over femoral for its lower bleeding risk and faster ambulation — the TR Band radial compression protocol), guide catheter engagement, lesion crossing with a 0.014-inch coronary guidewire, pre-dilation with a semi-compliant balloon, and deployment of a third-generation drug-eluting stent (e.g., Absorb BVS successor platforms, Orsiro biodegradable polymer sirolimus stent, Resolute Onyx zotarolimus stent, or Abbott Xience everolimus stent). Post-dilation with a non-compliant balloon at high pressure (16–20 atm) is performed to ensure full stent expansion. ADVANCED AND COMPLEX PCI TECHNIQUES: • Intravascular Imaging-Guided PCI (IVUS/OCT): Optical coherence tomography (OCT) provides near-histological resolution (10–20 µm) of plaque morphology, stent strut apposition, and edge dissections. IVUS is superior for ostial left main lesions. Multiple randomised trials (ILUMIEN IV, ULTIMATE) confirm imaging guidance reduces target vessel failure by 25–30% versus angiography-alone guidance. • Physiological Assessment (FFR/iFR/RFR): A pressure wire is advanced distal to the stenosis; FFR ≤0.80 or iFR ≤0.89 confirms haemodynamic significance. Deferring PCI for FFR >0.80 lesions is safe and avoids unnecessary stenting (DEFER, FAME, FAME 2 trial data). • Rotational Atherectomy (Rota-ablation): A diamond-tipped burr rotating at 140,000–180,000 rpm ablates heavily calcified plaques that cannot be adequately pre-dilated, enabling stent delivery and full expansion. Used in approximately 5–8% of complex PCI cases. • Orbital Atherectomy: The Diamondback 360° system uses an elliptical diamond-coated crown to sand down calcium on both sides of the vessel with a single-pass technique. • Laser Atherectomy (Excimer Laser Coronary Angioplasty, ELCA): Used for in-stent restenosis, uncrossable lesions, and thrombus-containing lesions. • Chronic Total Occlusion (CTO) PCI: A subspecialty technique using antegrade and retrograde approaches (retrograde via collateral channels), wire escalation algorithms (e.g., Hybrid Algorithm), and specialised CTO guidewires (Confianza Pro 12, Gaia series). Success rates exceed 85–90% in dedicated CTO programmes. • Bifurcation PCI: Techniques range from the provisional single-stent approach (preferred) to dedicated two-stent strategies: Culotte, Mini-Crush, Double-Kissing (DK) Crush — the latter proven superior in left main bifurcation disease (DKCRUSH-V trial). • Multivessel PCI with Haemodynamic Support: In patients with severely reduced LVEF (<30%), complex multivessel disease, or cardiogenic shock, percutaneous left ventricular assist devices (Impella CP or Impella 5.5) or intra-aortic balloon pump (IABP) provide circulatory support during high-risk PCI. • Bioresorbable Vascular Scaffolds (BVS) and Drug-Coated Balloons (DCB): DCBs (paclitaxel or sirolimus-coated) are particularly useful for in-stent restenosis and small vessels where permanent metal implantation is undesirable. • Transcatheter Heart Valve Procedures (Structural): High-volume cardiac centres in India and the UAE also perform TAVI/TAVR for severe aortic stenosis and MitraClip for mitral regurgitation, providing a full structural heart programme for patients with combined pathology. MEDICAL THERAPY (MANDATORY ADJUNCT TO PCI): • Antiplatelet: Aspirin 75–100 mg lifelong PLUS a P2Y12 inhibitor (ticagrelor 90 mg BD or prasugrel 10 mg OD preferred over clopidogrel for ACS; clopidogrel acceptable for stable CAD or high bleeding risk) for 6–12 months DAPT • Anticoagulation during procedure: Unfractionated heparin (UFH) titrated to ACT 250–300 seconds; bivalirudin (Angiomax) as an alternative in STEMI or HIT • High-intensity statin therapy: Rosuvastatin 20–40 mg or atorvastatin 40–80 mg initiated immediately • ACE inhibitor or ARB: For LVEF <40% or hypertension • Beta-blocker: For post-MI LV dysfunction or ongoing ischaemia • SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists for patients with concomitant type 2 diabetes and established cardiovascular disease (proven cardiovascular mortality reduction in EMPA-REG OUTCOME and LEADER trials)
Recovery
PHASE 1 — PRE-ARRIVAL AND REMOTE CONSULTATION (2–4 weeks before travel): • Patient shares medical records, recent ECG, echocardiogram, stress test reports, and coronary angiography images (if available) with GAF Healthcare's medical team • A GAF-affiliated senior interventional cardiologist reviews records and provides a written Second Opinion with a personalised treatment plan, estimated cost, and hospital recommendation • GAF Healthcare assists with e-Medical Visa application (India) or UAE entry visa coordination • Pre-procedure checklist dispatched: medications to continue or withhold (metformin stopped 48 hours before contrast, anticoagulants bridged per protocol), nil-by-mouth instructions, allergy declaration PHASE 2 — ARRIVAL AND PRE-PROCEDURE WORKUP (Day 1): • GAF airport representative meets patient and attendant; private transfer to hospital • Hospital admission and allocation of private room • Cardiology consultant review and clinical examination • Same-day diagnostics: 12-lead ECG, 2D echocardiogram, blood panel (troponin, renal function, CBC, coagulation, HbA1c), chest X-ray • Coronary CT angiography with CT-FFR if coronary anatomy not previously defined by invasive angiogram • Anaesthesia review (PCI is performed under local anaesthesia with conscious sedation; general anaesthesia reserved for haemodynamically unstable patients or complex CTO cases) • Patient and attendant briefed on procedure, risks, and consent obtained • Radial artery Allen's test performed to confirm dual-hand circulation before transradial access • Pre-procedure DAPT loading: ticagrelor 180 mg or clopidogrel 600 mg; aspirin 300 mg PHASE 3 — THE PROCEDURE (Day 2, Duration: 45 minutes to 3 hours depending on complexity): • Patient transferred to the cardiac catheterisation laboratory (Cath Lab), positioned on the angiography table • Local anaesthesia and radial artery sheath insertion (6F or 7F) • Diagnostic coronary angiography performed first to confirm anatomy if not previously done • Heparin administered IV (70–100 units/kg); ACT monitored every 30 minutes • Guide catheter engaged at coronary ostium; target lesion crossed with 0.014-inch guidewire • FFR/iFR measurement performed if stenosis severity is ambiguous • OCT or IVUS run for lesion assessment and stent sizing • Pre-dilation balloon inflated; stent deployed under fluoroscopy with optimal positioning • Post-dilation with non-compliant balloon; final OCT/IVUS to confirm full expansion and apposition • Sheath removed; radial TR Band haemostasis applied • Patient transferred to Coronary Care Unit (CCU) for 12–24 hours of telemetry monitoring PHASE 4 — POST-PROCEDURE HOSPITAL RECOVERY (Days 2–4): • CCU monitoring: continuous ECG telemetry, hourly blood pressure, oxygen saturation • Serial ECGs at 6 hours and 24 hours post-procedure • Post-procedure echocardiogram to assess LVEF and wall motion • Renal function rechecked at 24 and 48 hours post-contrast • Radial site inspected for haematoma, pseudoaneurysm, or access site complications • Cardiorespiratory physiotherapy initiated: deep breathing exercises, graduated ambulation from Day 1 post-procedure • Medications optimised: DAPT, high-intensity statin, ACE inhibitor/ARB, beta-blocker, SGLT2 inhibitor if indicated • Patient education: DAPT compliance (never stop without cardiologist advice), red-flag symptoms (recurrent chest pain, breathlessness, access site swelling), dietary and lifestyle modification counselling • Discharge criteria: haemodynamically stable, no access site complications, renal function stable, oral medications initiated PHASE 5 — IN-COUNTRY RECOVERY (Days 4–14): • GAF arranges hotel or serviced apartment near hospital for patient and attendant • Outpatient review at Day 5–7: wound check, ECG, blood pressure monitoring, medication reconciliation • Cardiac rehabilitation programme initiated (supervised walking programme, heart rate monitoring) • Mild activities permitted: walking on flat surfaces, self-care activities • Restrictions: no driving for 5–7 days (radial access); no heavy lifting >5 kg for 2 weeks; no strenuous exercise for 4 weeks • Short-haul flight (under 4 hours) cleared at Day 5–7 by cardiologist if LVEF >40% and no complications • Long-haul intercontinental flight cleared at Day 10–14; graduated ambulation every 2 hours in-flight, compression stockings, adequate hydration advised PHASE 6 — FOLLOW-UP AFTER RETURN HOME: • GAF Healthcare provides a comprehensive discharge summary, medication list, and follow-up protocol for the patient's home cardiologist • Teleconsultation with the treating cardiologist at 1 month, 3 months, and 6 months post-procedure • Exercise stress test or nuclear MPI recommended at 9–12 months to assess stent patency • Lifelong aspirin; P2Y12 inhibitor for minimum 6 months (12 months for ACS); never discontinue DAPT without prior cardiology consultation
Risks to be aware of
Angioplasty and coronary stenting is a well-established, low-risk procedure in experienced hands, but patients must be counselled on specific complications to make a fully informed decision. Vascular access site complications — including radial artery spasm, haematoma, pseudoaneurysm, or radial artery occlusion — occur in 1–3% of transradial cases and are generally minor. The most feared acute complication is stent thrombosis: an abrupt occlusion of the stent by thrombus, occurring in <1% of cases acutely and <0.5% per year thereafter; it is catastrophically associated with myocardial infarction and death, and is almost entirely preventable by strict adherence to dual antiplatelet therapy (DAPT). Patients must never self-discontinue clopidogrel, ticagrelor, or prasugrel without explicit cardiologist guidance, particularly within the first 12 months of stent implantation. Contrast-induced nephropathy (CIN) occurs in 1–5% of patients — risk is substantially higher in those with pre-existing chronic kidney disease (eGFR <60 mL/min), diabetes, or myeloma; mitigation strategies include IV pre-hydration with normal saline or sodium bicarbonate, use of iso-osmolar or low-osmolar contrast agents (iohexol, iopamidol), and minimising contrast volume. Coronary artery dissection or perforation are rare (<0.5%) but potentially life-threatening procedural complications requiring emergent pericardiocentesis or covered stent deployment. Radiation exposure from fluoroscopy is minimised by the use of low-dose pulse fluoroscopy protocols and experienced operators. In-stent restenosis — symptomatic re-narrowing within the stent due to neointimal hyperplasia — occurs in 3–7% of drug-eluting stent recipients at 1–2 years, treatable by repeat PCI with a drug-coated balloon or second DES. For patients with multivessel CAD and high SYNTAX scores, the risk of repeat revascularisation is meaningfully higher with PCI than with coronary artery bypass grafting (CABG); the Heart Team decision-making process — involving an interventional cardiologist, cardiac surgeon, and the patient — is essential to ensure the correct revascularisation strategy is chosen for complex disease. Patients travelling internationally should carry a stent implantation card detailing stent brand, size, implantation date, and antiplatelet regimen for presentation to any emergency physician if chest pain recurs during their journey.
Why GAF Healthcare
GAF Healthcare provides a fully coordinated, concierge-level medical travel service covering every non-clinical aspect of the patient's journey to India or the UAE. VISA ASSISTANCE — INDIA: GAF Healthcare's case coordinators prepare and guide patients through the Indian e-Medical Visa application, which is available to citizens of over 160 countries. The e-Medical Visa is processed online in 3–5 business days, is valid for 60 days with triple entry, and permits entry through 30 designated international airports including Delhi Indira Gandhi, Mumbai Chhatrapati Shivaji, Chennai, Hyderabad, and Kochi. GAF provides all required supporting documentation: a formal hospital invitation letter on hospital letterhead, a treatment cost estimate, and guidance on the photograph and passport specifications required by the Indian Visa Application Centre. VISA ASSISTANCE — UAE (DUBAI AND ABU DHABI): Citizens of GCC countries, the European Union, the United States, United Kingdom, Canada, Australia, and approximately 50 additional nationalities receive visa-free entry or visa-on-arrival access to the UAE for 30–90 days — no pre-approval required. For nationalities requiring advance UAE visas, GAF facilitates a UAE Medical Treatment Visa or Tourist Visa application through its UAE partner hospitals, which serve as sponsors. The process typically takes 3–7 business days. AIRPORT TRANSFERS AND GROUND LOGISTICS: A dedicated GAF Healthcare representative meets the patient and attendant at the arrivals gate of all major partner airports, carrying a personalised name card. Private, air-conditioned vehicle transfers are arranged to the hospital — not shared taxis or public transport. Wheelchair assistance and porter services are pre-arranged where required. Return transfers to the airport at discharge are included in the GAF coordination package. MEDICAL INTERPRETERS AND TRANSLATORS: GAF Healthcare provides professional medical interpreters fluent in Arabic, Russian, French, Swahili, Uzbek, and other languages upon request. Interpretation is available in-person during consultations, procedures, and discharge briefings, as well as via video call for patients who prefer remote support. All medical documents — consent forms, discharge summaries, prescription records — are translated into the patient's preferred language. ATTENDANT ACCOMMODATION: GAF Healthcare arranges accommodation for one or two accompanying family members or caregivers within 1–3 kilometres of the treating hospital. Options range from budget-friendly serviced guesthouses to 4-star hotels depending on the patient's preference and budget. In many partner hospitals, attendant stay within the private room is included in the room rate; GAF confirms these details during the pre-admission planning stage. COMMUNICATION AND 24/7 SUPPORT: A dedicated GAF case manager is assigned to each patient before departure and remains the single point of contact throughout the entire medical journey — from visa paperwork to post-discharge teleconsultation scheduling. A 24/7 emergency helpline is available for any clinical or logistical concern arising during the patient's stay.
Common questions about Angioplasty & Stenting
What is the cost of Angioplasty and Coronary Stenting in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after angioplasty and stenting?
What is the success rate of angioplasty and coronary stenting?
How GAF Healthcare Assists in Choosing the Best Hospital for Angioplasty & Stenting in Dubai, UAE
Discover the Top Hospitals for Angioplasty & Stenting in Dubai, UAE
This page lists 3 accredited cardiothoracic & vascular surgery hospitals in Dubai, UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about angioplasty & stenting in Dubai, UAE
How many cardiothoracic & vascular surgery hospitals are listed in Dubai, UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Are there cardiothoracic & vascular surgery hospitals for this in other UAE cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for angioplasty & stenting in Dubai, UAE.
Contact us to report an inaccuracy on this page.